Funded Projects
New Prime Editing and non-viral delivery strategies for Gene Therapy
The EdiGenT project introduces a non-viral nanoparticle-based system with minimal side effects for the delivery of gene editing components in cells.
Developing novel inhaled bioengineered Extracellular Vesicle RNA based advanced therapeutics, delivered by tailored aerosol delivery technology for the treatment of lung cancer
INSPIRE will employ an aerosol-based approach to efficiently deliver genetically modified EVs from mesenchymal stromal cells through the mucus barrier, as a therapy against lung cancer. Cellularis will bioengineer innovative patient-derived ECM-tumor-stroma organoid models that recapitulate ECM aberrant crosslinking.
